Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants

Kiyoto Tsuchiya; Tsunefusa Hayashida; Akinobu Hamada; Shingo Kato; Shinichi Oka; Hiroyuki Gatanaga

doi:10.1097/QAI.0000000000000222

Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants

Kiyoto Tsuchiya, Tsunefusa Hayashida, Akinobu Hamada, Shingo Kato, Shinichi Oka, Hiroyuki Gatanaga

Department of Microbiology and Immunology

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Adenosine triphosphate-binding cassette transporter G2 (ABCG2) is expressed on the cerebrospinal fluid (CSF) side of choroid plexus epithelial cells, which form the blood-CSF barrier. Raltegravir was recently identified as a substrate of ABCG2. In the present study, we analyzed the relationship between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and raltegravir concentrations in 31 plasma and 14 CSF samples of HIV-infected patients treated with raltegravir-containing regimens. The mean CSF raltegravir concentration was significantly lower in CA (25.5 ng/mL) and AA (<10 ng/mL) genotypes at position 421 in ABCG2 gene compared with CC (103.6 ng/mL) genotype holders (P = 0.016).

Original language	English
Pages (from-to)	484-486
Number of pages	3
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	66
Issue number	5
DOIs	https://doi.org/10.1097/QAI.0000000000000222
Publication status	Published - 2014 Aug 15

Keywords

Adenosine triphosphate-binding cassette transporter G2
Antiretroviral therapy
Blood-cerebrospinal fluid barrier
Cerebrospinal fluid concentrations
Raltegravir

ASJC Scopus subject areas

Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/QAI.0000000000000222

Cite this

@article{20836ea9236448de8bc51c37e325203c,

title = "Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants",

abstract = "Adenosine triphosphate-binding cassette transporter G2 (ABCG2) is expressed on the cerebrospinal fluid (CSF) side of choroid plexus epithelial cells, which form the blood-CSF barrier. Raltegravir was recently identified as a substrate of ABCG2. In the present study, we analyzed the relationship between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and raltegravir concentrations in 31 plasma and 14 CSF samples of HIV-infected patients treated with raltegravir-containing regimens. The mean CSF raltegravir concentration was significantly lower in CA (25.5 ng/mL) and AA (<10 ng/mL) genotypes at position 421 in ABCG2 gene compared with CC (103.6 ng/mL) genotype holders (P = 0.016).",

keywords = "Adenosine triphosphate-binding cassette transporter G2, Antiretroviral therapy, Blood-cerebrospinal fluid barrier, Cerebrospinal fluid concentrations, Raltegravir",

author = "Kiyoto Tsuchiya and Tsunefusa Hayashida and Akinobu Hamada and Shingo Kato and Shinichi Oka and Hiroyuki Gatanaga",

year = "2014",

month = aug,

day = "15",

doi = "10.1097/QAI.0000000000000222",

language = "English",

volume = "66",

pages = "484--486",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants

AU - Tsuchiya, Kiyoto

AU - Hayashida, Tsunefusa

AU - Hamada, Akinobu

AU - Kato, Shingo

AU - Oka, Shinichi

AU - Gatanaga, Hiroyuki

PY - 2014/8/15

Y1 - 2014/8/15

N2 - Adenosine triphosphate-binding cassette transporter G2 (ABCG2) is expressed on the cerebrospinal fluid (CSF) side of choroid plexus epithelial cells, which form the blood-CSF barrier. Raltegravir was recently identified as a substrate of ABCG2. In the present study, we analyzed the relationship between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and raltegravir concentrations in 31 plasma and 14 CSF samples of HIV-infected patients treated with raltegravir-containing regimens. The mean CSF raltegravir concentration was significantly lower in CA (25.5 ng/mL) and AA (<10 ng/mL) genotypes at position 421 in ABCG2 gene compared with CC (103.6 ng/mL) genotype holders (P = 0.016).

AB - Adenosine triphosphate-binding cassette transporter G2 (ABCG2) is expressed on the cerebrospinal fluid (CSF) side of choroid plexus epithelial cells, which form the blood-CSF barrier. Raltegravir was recently identified as a substrate of ABCG2. In the present study, we analyzed the relationship between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and raltegravir concentrations in 31 plasma and 14 CSF samples of HIV-infected patients treated with raltegravir-containing regimens. The mean CSF raltegravir concentration was significantly lower in CA (25.5 ng/mL) and AA (<10 ng/mL) genotypes at position 421 in ABCG2 gene compared with CC (103.6 ng/mL) genotype holders (P = 0.016).

KW - Adenosine triphosphate-binding cassette transporter G2

KW - Antiretroviral therapy

KW - Blood-cerebrospinal fluid barrier

KW - Cerebrospinal fluid concentrations

KW - Raltegravir

UR - http://www.scopus.com/inward/record.url?scp=84904465734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904465734&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000000222

DO - 10.1097/QAI.0000000000000222

M3 - Article

C2 - 24872134

AN - SCOPUS:84904465734

VL - 66

SP - 484

EP - 486

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 5

ER -

Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this